Last reviewed · How we verify
Lactobacillus salivarius CECT5713
At a glance
| Generic name | Lactobacillus salivarius CECT5713 |
|---|---|
| Sponsor | Universidad Complutense de Madrid |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Modulation of Reproductive Microbiota by Ligilactobacillus Salivarius CECT5713 (NA)
- Application of Lactobacillus Salivarius CECT5713 in Infertility of Unknown Origin (PHASE2)
- Safety Assessment of Lactobacillus Salivarius CECT5713 in 6 Months Old Children (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: